- About WXPress
- WXPress is your window into the world of WuXi AppTec and our global partners.
- Sitemap
- Events
- Contact
- Please reach out with any business inquires.
- communications@wuxiapptec.com
© 2026 WuXi AppTec. All Rights Reserved.Privacy Policy
March 30, 2023 ~ March 30, 2023
7AM-11AM PDT and 7AM-11PM PDT
Dear Colleagues and Friends,
Thanks to the wonderful support from so many of you, WuXi AppTec’s in-person WuXi Global Forum 2023, hosted during the J.P. Morgan Healthcare Conference in San Francisco, was a great success with 4,000 RSVPs and over 200 audience questions submitted.
After receiving numerous requests to make it available online and to continue these important conversations, we are creating a new online program series to not only recap the key moments of the Forum for the broader healthcare community but also showcase leading organizations around the world. The series is inspired by and will focus on the “BOLD” theme: Breaking Barriers, Opening New Horizons, Leading Next Generation Therapeutics, and, Delivering on the Promise for Patients.
We are delighted to invite you to join us for the first episode of the series, a broadcast of our recent WuXi Global Forum, to be premiered across global time zones on March 30, 2023 at 7-11AM PDT and 7-11PM PDT respectively.
We encourage you to tune in and to be on the lookout for future BOLD programming, where you will hear from thought leaders and experts who are taking bold actions to advance breakthroughs for patients.
A very special THANK YOU again to our esteemed speakers for their valuable insights. In a year of challenges and opportunities, their leadership, and perspectives continue to be an inspiration for us all.
Hui Cai, Program Chair and Vice President, WuXi AppTec
Minzhang Chen, Co-CEO, WuXi AppTec
Todd Golub, Director, Broad Institute of MIT & Harvard
John Ngai, Director, NIH BRAIN Initiative
Vijay Pande, General Partner, Andreessen Horowitz
Aviv Regev, Head, Genentech Research and Early Development
Michael Severino, CEO, Tessera Therapeutics; CEO-Partner, Flagship Pioneering
Session Leader: Mathai Mammen, Executive Vice President of R&D, Johnson & Johnson Pharmaceuticals (in transition)
Ros Deegan, CEO, OMass Therapeutics
Dan Nomura, Professor of Chemical Biology and Molecular Therapeutics, University of California, Berkeley
Nancy Pryer, CSO, Ambagon Therapeutics
Lance Stewart, Chief Strategy and Operations Officer, Institute for Protein Design, University of Washington
Session Leader: Karen Tkach Tuzman, Senior Editor and Head of Discovery & Preclinical Development, BioCentury
Tom Barnes, CEO, Orna Therapeutics
John Mendlein, Chairman, Laronde; Executive Partner, Flagship Pioneering
Romesh Subramanian, CEO, Ascidian Therapeutics
Michelle Werner, CEO, Alltrna; CEO-Partner, Flagship Pioneering
Session Leader: Nina Kjellson, General Partner, Canaan
Ken Drazan, Chairman, CEO, Co-Founder, ArsenalBio
Keith Gottesdiener, President & CEO, Prime Medicine
Laura Shawver, President & CEO, Capstan Therapeutics
Catherine Stehman-Breen, CEO, Chroma Medicine
Session Leader: Edward Hu, Vice Chairman, Global Chief Investment Officer, WuXi AppTec
Giulio Draetta, SVP & CSO, MD Anderson Cancer Center
Stephen Hauser, Director, UCSF Weill Institute for Neurosciences; Professor, Department of Neurology, University of California, San Francisco
Joseph Wu, Director of Stanford Cardiovascular Institute; President-Elect of American Heart Association
Session Leader: Christiana Bardon, Co-Managing Partner of BioImpact Capital, an MPM affiliate
Juergen Eckhardt, SVP & Head of Leaps by Bayer
Sofia Ioannidou, Partner, Andera Partners
Carol Suh, Partner, ARCH Venture Partners
Sze-Wee Tan, Assistant Chief Executive, Innovation and Enterprise Group, Singapore Agency for Science, Technology and Research (A*STAR)
Session Leader: Michal Preminger, Regional Head, Johnson & Johnson Innovation East North America
Steve Yang, Co-CEO, WuXi AppTec
